HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection

Author:

Ghosn Jade1,Assoumou Lambert2,Lascoux-Combe Caroline3,Peytavin Gilles4ORCID,Amat Karine5,Gabassi Audrey6,Le Minh P4,Nzalakanda Robert2,Valin Nadia7,Landman Roland1,Chaix Marie-Laure6,Delaugerre Constance6

Affiliation:

1. Service de Maladies Infectieuses, Hôpital Bichat, Infection Modelisation Antimicrobial Evolution, UMR1137, INSERM, Université de Paris, Paris, France

2. INSERM, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France

3. Service de Maladies Infectieuses, Hôpital Saint Louis, AP-HP, Paris, France

4. Service de Pharmacologie et Toxicologie, Hôpital Bichat, AP-HP, Infection Modelisation Antimicrobial Evolution, INSERM UMR1137, UF301, Université de Paris, Paris, France

5. Institut de Médecine et d'Epidémiologie Appliquées-Fondation Léon Mba, Hôpital Bichat-Claude Bernard, Paris, France

6. Service de Virologie, Hôpital Saint Louis, AP-HP, INSERM U944, Université de Paris, Paris, France

7. Service de Maladies Infectieuses et Tropicales, Hôpital Saint Antoine, AP-HP, Paris, France

Abstract

Abstract We compared the proportion of participants achieving first undetectable HIV-1 RNA (VL) in seminal plasma (SP) and blood plasma (BP) in 19 men starting dolutegravir-based regimen at primary HIV infection. At baseline, median VL was 6.5 (interquartile range [IQR], 5.6–7.9) and 4.5 (IQR, 3.5–5.0) log10 copies/mL in BP and SP, respectively. Between baseline and week 48, significantly higher proportion of participants achieved first VL below limit of quantification in SP (93.0%) than in BP (84.2%; P = .008). Time to first undetectable VL was 8 weeks in SP (95% confidence interval [CI], 5.6–10.4) and 24 weeks in BP (95% CI, 14.1–33.9).

Funder

ViiV Healthcare

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3